维里迪安治疗

最新新闻

• 评级变动
  Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
  TipRanks · 2026/6/29
• 评级变动
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/6/17
• LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
  TipRanks · 2026/6/17
• 评级变动
  Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/6/28
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
  TipRanks · 2026/6/28

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。